Scaling up your business
Scaling up your biotech or biomanufacturing business means building the connections, expertise, and tools needed to expand operations, access new markets, and achieve sustainable growth. The EU provides a variety of resources to help SMEs in biotech or biomanufacturing succeed.
Scaling up: 'lab to fab'
The following tools and projects may help you to bring your innovations from a small-scale laboratory environment to an industrial scale:
- Pilots4U: maps all existing open access pilot and demo-infrastructures across Europe and creates an easily accessible network.
- InvestEU Advisory Hub: helps biotech companies in reviewing and designing the business/financial model.
- SCALE-UP: helps businesses identify and scale-up innovative and sustainable bio-based value chains that build on regional resources.
- MainstreamBIO: offers digital tools to get small-scale bio-based solutions into mainstream practice across rural Europe.
- Technology Centre Mapping | European Monitor of Industrial Ecosystems: gain insights into market trends, technological advancements, and opportunities. EMI also maps around 50 biotech-focused technology centres across Europe that provide R&D support, mentoring, and product development expertise.
Insights and expertise for growth
Expand your knowledge base and leverage EU-backed data-sharing platforms, strategic insights, and expertise to drive innovation and collaboration:
- European Monitor for Industrial Ecosystems (EMI): gain insights into market trends, technological advancements, and opportunities. EMI also maps around 50 biotech-focused technology centres across Europe that provide R&D support, mentoring, and product development expertise.
- Open science and data collaboration: platforms like the European Open Science Cloud (EOSC) and the European Health Data Space (EHDS) enable biotech researchers to access shared datasets across the EU, boosting collaboration in fields like epidemiology and personalised medicine.
- Policy and market insights: resources like CORDIS and the EU Science Hub offer data, reports, and strategic insights on EU biotech policies, market trends, and funding opportunities.
Access to markets
Scaling biotech companies need clear pathways to enter local, EU, and global markets. This involves understanding regulatory frameworks, identifying distribution partners, and leveraging networks to increase market visibility.
- Enterprise Europe Network (EEN): EEN helps you with personalised services free of charge to innovate, finance, and expand your business into new markets, get funding and connect with partners in more than 60 countries.
- EU Access2Markets Database: For international market entry, check tariffs, regulatory requirements, and trade barriers using the EU’s database.
Business support
Build strategic connections with industry leaders, researchers, and public authorities to foster partnerships, share expertise, and unlock growth opportunities for your biotech business.
Networking and collaboration
- Enterprise Europe Network (EEN): connect with business and innovation partners worldwide. EEN offers tailored advice on expanding internationally, finding funding, and meeting regulatory requirements.
- European Cluster Collaboration Platform (ECCP): ECCP supports regional networks of businesses, research institutions, and other stakeholders that drive innovation and competitiveness in specific industries. These clusters help SMEs with access to innovation, networking and partnerships, shared resources and expertise, increased competitiveness, easier access to funding and support. More than 1500 clusters are listed, of which around 90 in biotech.
- Regional Innovation Valleys (RIVs): these initiatives connect regional innovation ecosystems across Europe, helping biotech SMEs collaborate with academic institutions, industry leaders, and public authorities. RIVs aim to accelerate innovation, particularly in key areas like health, green technologies, and digital transformation. Check the RIV Match Making Map for potential partners or consult local authorities.